Intriguingly, phase I-II studies in different malignancies, including CCA, revealed satisfactory outcomes about overall safety and tolerability, along with improving ORR and PFS rates [129,133,134,135,136,137], suggesting that, together with PARP, Wee1 might represent a prominent target to develop in setting up novel therapeutic programs for CCA patients. The gene discussed is PARP1; the disease is cholangiocarcinoma.